India's Hetero says COVID-19 drug reduces hospitalisations in late-stage trial

Molnupiravir is an antiviral therapy Merck & Co is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalised COVID-19 patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3hp9AeS
via IFTTT